11 clinical trials to watch in 2025 Nature Medicine nature.com/articles/s4159…

Intellectual property training should be embedded in the biomedical education process go.nature.com/4iCtdhc

Lots of firsts for FDA approvals in 2024: First schizophrenia drug that doesn't block dopamine receptors First drug for non-alcoholic steatohepatitis First biparatopic antibody (2 epitopes in one molecule) First mRNA vaccine not for Covid First TCR-engineered T cell therapy

Bispecific T cell receptor molecules designed to wipe out HIV-infected T cells offer glimpses of a cure nature.com/articles/s4158… rdcu.be/d5Mzg

The Cognitive Disorder Atlas.

Antibióticos & su mecanismo de acción que debes recordar:

Thrilled to introduce our Cell Reports @cellreports article, showing how the iconic '#Hallmarks of #Cancer' are located in the space of real human primary tumors. A team effort co-led by Eduard Porta Eduard Porta , Matthew H. Bailey, and yours truly. #SpatialBiology #Visium

❗PRIMERAS IMAGENES del MODO RATON de NINTENDO SWITCH 2 ➡️ Mediante una patente oficial de Nintendo que se acaba de hacer pública, se ha podido ver por primera vez las posibles distintas formas de jugar que tendríamos en Nintendo Switch 2 con el modo ratón de los nuevos Joy-Con.

A new European platform for advancing regulatory science research tinyurl.com/3989u5fz Launching in 2025, the European Platform for Regulatory Science Research will bring together academia, regulators and other stakeholders to accelerate regulatory science research solutions

FDA approves TROP2-targeted antibody–drug conjugate for breast cancer nature.com/articles/d4157… Daiichi Sankyo and AstraZeneca’s new ADC datopotamab deruxtecan will compete with Gilead/Immunomedics’ sacituzumab govitecan, which is expected to have sales of ~$1.7 billion in 2025

Our latest Chief Economist studies reveal key trends in quantum tech, future mobility and circular economy solutions. ♻️ Dive into the insights here: bit.ly/CEUstudies #EPOStudy #QuantumTech #CircularEconomy

Europe’s oncology startup ecosystem is thriving in early growth, with the UK, France and Germany leading. But late-stage scaling remains a challenge compared to the US. 🔗 Find more insights in our #EPOStudy: epo.org/trends-oncology

📊 The big reveal: The 2024 #EPOPatentIndex is here! Have a look if you want to know: 🔍 Where is technology heading? 📈 Which industries are booming? 🌍 Which regions led in patenting activity at the EPO in 2024? Have a look: youtu.be/inQz3P009Qc

The Global Dossier lets you view file histories of patent family members across major IP offices, all from one place via the European Patent Register. 📽️ Watch our short video to learn more: bit.ly/2T7F8cJ

From beats🎧 to rights ©️ Copyright helps music creators get credited and paid for their work. But how much more do you know about copyright? Swipe through for five fun facts ➡️

📈 Consistent growth, accelerating ambitions! Patent filings for space propulsion technologies have risen by 9% annually over the last 20 years, most sharply since 2011. 🔍 Discover more in this EuropeanPatentOffice report with European Space Policy Institute (ESPI) & European Space Agency: epo.org/insight-propul… #EPOStudy

¿Recuerdas cuando te uniste a X? ¡Yo sí! #MiAniversarioDeX

Hace seis décadas, la Facultad de Química de la UNAM dio un paso decisivo: crear un Posgrado que uniera la pasión por el conocimiento con el compromiso en la formación de profesionales de la Química. 📚 bit.ly/4nsq4CW

🧬 The gut microbiome shapes immune responses and may boost immunotherapy in cancer. New strategies, like FMT, probiotics, and diet, are moving into trials, with growing clinical relevance. Nature Reviews Drug Discovery 🔗 doi.org/10.1038/s41573… #Cancer #Immunotherapy #Microbiome #ICI

The rise of China’s pharmaceutical industry from 2015–2024 nature.com/articles/d4157… This new article analyses the growth in drug innovation in China, the underlying environmental factors and strategic trends such as the outlicensing of assets originating in Chinese companies